MetaCap

Faeth Therapeutics Inc. (FTH)

NASDAQ: FTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD

7.88-0.81 (-9.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FTH stock chart

Technical analysis

Key statistics

All statistics
Market cap
$203.65M
EPS (TTM)
-$22.50
52-week range
7.45 – 42.14
Day range
7.85 – 9.13
Volume / Avg
419.09K / 500.25K
Beta
—

52-week range

$7.45$42.14

FTH stock today

Shares of Faeth Therapeutics (FTH) finished lower on Nov 20 at $7.88, a drop of 9.32% or $0.81 per share, versus the S&P 500's 3.70% decline. At this level, FTH sits near the bottom of its 52-week range of $7.45 to $42.14: 81.3% below the high, set on Sep 8, 2026 and 5.8% above the low. FTH is down 26.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 9.6%.

Faeth Therapeutics has posted a net loss over the last twelve months (EPS of -$22.50), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Faeth Therapeutics

Company profile

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Anand Parikh Esq., J.D.
Headquarters
Rockville, MD
Employees
29
IPO year
2021

Financial highlights

Full financials

Faeth Therapeutics reported a net loss of $21.1 million, compared with a loss of $30.2 million a year earlier. Diluted earnings per share came in at -$16.72.

Faeth Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-21.09M$-30.16M$-34.10M$-48.59M$-36.79M
EPS (diluted)$-16.72$-24.01$-1.22$-1.58$-1.33

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$56.15+612.56%

  • Strong buy 3
  • Buy 12
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $40.00High $69.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.79 vs $-0.66
Surprise
-19.70%

FTH news

All FTH news

Faeth Therapeutics peers

Health Care sector
FTH peer companies
CompanyPrice% ChgMarket capCompare
BCYCBicycle Therapeutics plc ADR2.90-4.92%$203.27Mvs FTH
DRUGBright Minds Biosciences Inc.20.40-1.45%$201.23Mvs FTH
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs FTH
NGENNervGen Pharma Corp.1.85-3.91%$198.55Mvs FTH
CYPHCypherpunk Technologies Inc.1.41-18.02%$210.15Mvs FTH
BIOABioAge Labs Inc.4.28-9.13%$196.67Mvs FTH
YARWYarrow Bioscience Inc.12.90-9.35%$196.53Mvs FTH
ACIUAC Immune SA1.95-8.45%$193.88Mvs FTH

Indexes, lists and sector

Faeth Therapeutics stock FAQ

What is Faeth Therapeutics's stock price today?

FTH last traded at $7.88 as of Nov 20, 4:00 PM EST, down 9.32% on the day. Prices are delayed at least 15 minutes.

Does Faeth Therapeutics pay a dividend?

No. Faeth Therapeutics does not currently pay a regular cash dividend.

Who is Faeth Therapeutics's CEO?

Mr. Anand Parikh Esq., J.D. is the chief executive officer of Faeth Therapeutics Inc., which has about 29 employees.

Has FTH ever split its stock?

Yes. The most recent FTH stock split was a 1-for-20 split on Jun 17, 2025.

What is the FTH 52-week high?

The 52-week high for FTH is $42.14 and the 52-week low is $7.45. The stock is currently 81.3% below its high.

Compare FTH